Sonova Holding AG stock (CH0012549785): hearing specialist in focus after recent earnings update

Hearing-care group Sonova Holding AG remains in the spotlight after its latest earnings release and guidance update. Investors are watching how the Swiss company navigates demand trends, reimbursement changes and competitive pressure in hearing aids and cochlear implants.

Sonova Holding AG has stayed on investors’ radar following the release of its recent financial results and an updated outlook that highlighted both solid demand for hearing solutions and ongoing cost pressures in key markets, according to information published in the company’s investor materials and earnings communications in spring 2025Sonova investor information as of 05/2025. The Swiss-based hearing-care group reported continued revenue growth in its audiological care network and cochlear implants, while also flagging headwinds from reimbursement changes and currency moves. For US-focused investors, the results underline how a European medtech player with a global footprint is positioning itself in a structurally growing but competitive market.

In its latest full-year reporting cycle for the financial year 2024/25, released in May 2025, Sonova pointed to organic sales expansion driven by new product launches, higher volumes in premium hearing aids and increased contributions from its retail network, alongside acquisition effects in several European markets, according to the company’s presentation for that periodSonova media release as of 05/2025. At the same time, management confirmed its focus on efficiency programs intended to protect margins against inflationary pressure, labor shortages in parts of the healthcare system and unfavorable foreign-exchange translation.

As of: 25.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Sonova
• Sector/industry: Hearing-care medical technology and audiological services
• Headquarters/country: Stäfa, Switzerland
• Core markets: Europe, North America and Asia-Pacific hearing-care markets
• Key revenue drivers: Hearing aids, cochlear implants, audiological care retail network
• Home exchange/listing venue: SIX Swiss Exchange (ticker: SOON)
• Trading currency: Swiss franc (CHF)

Sonova Holding AG: core business model

Sonova Holding AG operates as a global provider of hearing-care solutions, combining the development and manufacturing of medical-grade hearing devices with a broad network of audiological care outlets. The business is structured around three main pillars: hearing instruments, cochlear implants and a vertically integrated retail network that offers diagnostics, fitting and long-term follow-up services to patients, according to the group’s company profile and segment reporting in its annual documentation for 2023/24 published in May 2024Sonova annual report as of 05/2024. This combination aims to deliver a full patient journey, from the first hearing test to device upgrades years later.

In the hearing instruments segment, Sonova designs and manufactures behind-the-ear, in-the-ear and receiver-in-canal devices under brands such as Phonak, Unitron and Hansaton, as well as connected accessories and software platforms that support precise fitting and remote support. These products are distributed both through third-party audiology practices and through Sonova’s own retail operations, which allows the group to capture value along the supply chain and better control the end-customer experience, according to its business description in the same 2023/24 annual report published in May 2024Sonova business review as of 05/2024. The cochlear implant division targets patients with more severe forms of hearing loss who may not benefit sufficiently from conventional hearing aids.

Sonova’s retail and audiological care network has expanded over the years through both organic growth and acquisitions in markets such as Germany, France, the United Kingdom, the United States and Canada, according to disclosure in the group’s annual report for 2022/23 issued in May 2023Sonova annual report as of 05/2023. Owning retail outlets enables Sonova to collect detailed feedback on patient preferences, device performance and reimbursement conditions, which can be fed back into product development and commercial strategy. This integrated structure is intended to strengthen customer loyalty and may provide a buffer against pricing pressure in certain wholesale channels.

Main revenue and product drivers for Sonova Holding AG

Revenue at Sonova is primarily generated through sales of hearing instruments, followed by its cochlear implant portfolio and audiological care services. In its financial year 2023/24, hearing instruments accounted for the majority of group sales, with growth supported by the introduction of advanced product platforms and expanding channel penetration, according to segment data in the company’s annual report released in May 2024Sonova financial report as of 05/2024. Key innovations have included rechargeable devices, enhanced speech-in-noise processing and Bluetooth-enabled connectivity, features aimed at improving comfort and daily usability for patients.

The cochlear implant business, while smaller in absolute revenue terms than hearing instruments, remains an important strategic driver because it addresses a segment of the hearing-loss population with high unmet medical need. Sonova reports implant system sales, upgrade procedures and related services within this division, with demand influenced by referral patterns from otolaryngologists, reimbursement decisions by public and private payers and competition from other implant manufacturers, as outlined in its 2022/23 and 2023/24 annual reports published in May 2023 and May 2024 respectivelySonova governance report as of 05/2024. Over time, upgrades and service contracts for implanted patients can create a recurring revenue stream.

Another important revenue influence comes from the group’s presence in audiological care, where Sonova operates retail chains and independent practices that sell both its own brands and third-party devices. This network benefits from demographic trends such as aging populations in North America, Europe and parts of Asia, which translate into a rising prevalence of age-related hearing loss, according to demographic projections from organizations such as the United Nations cited by the company in its 2023/24 annual reporting as of May 2024Sonova sustainability report as of 05/2024. Additionally, increasing awareness of the impact of untreated hearing loss on quality of life and productivity supports structural demand for professional diagnosis and fitting.

From a profitability standpoint, Sonova’s earnings profile is shaped by the mix between premium and mid-range products, retail versus wholesale channels, and the relative weight of hardware versus service revenues. Premium devices and implants typically offer higher gross margins but may be more sensitive to reimbursement decisions and consumer confidence. At the same time, investments in research and development, digital platforms and new store openings create upfront costs that are expected to be repaid through future sales growth, as discussed by management in earnings materials accompanying the full-year 2023/24 results released in May 2024Sonova news archive as of 05/2024. The company’s ability to balance innovation spending with cost control is therefore closely watched by market participants.

Why Sonova Holding AG matters for US investors

Although Sonova’s primary listing is on the SIX Swiss Exchange and its reporting currency is the Swiss franc, the company has a meaningful footprint in the United States through both device sales and audiological care operations. The US is one of the largest markets worldwide for hearing aids and cochlear implants, driven by demographic trends and comparatively high healthcare spending, and Sonova competes there alongside global peers in both the clinical and retail environments, according to its regional breakdowns in the annual reports for 2022/23 and 2023/24 published in May 2023 and May 2024Sonova operational review as of 05/2024. For US-based investors, exposure to Sonova can therefore offer an indirect play on hearing-care demand in their home market, while also introducing currency and regulatory diversification.

In addition, developments in the US regulatory environment, such as the introduction of over-the-counter hearing aids and evolving reimbursement rules under Medicare, Medicaid and private insurance, may influence Sonova’s strategy and product positioning. While the group’s main brands are traditionally dispensed through audiologists and hearing-care professionals, it has explored opportunities in more accessible channels and digital solutions, adjusting its portfolio to different price segments and service models, according to commentary from management in earnings and strategy materials released alongside the 2023/24 annual report in May 2024Sonova investor news as of 05/2024. US investors monitoring the stock may therefore pay attention not only to headline sales figures but also to how Sonova positions itself relative to changing customer expectations and new forms of competition in their domestic market.

Conclusion

Sonova Holding AG remains a key global player in hearing care, with a business model that spans device development, manufacturing and audiological services. Recent earnings updates and guidance from spring 2025 underline the company’s focus on leveraging new product platforms and its retail network to capture structural growth in hearing aids and cochlear implants, while tackling cost inflation and currency headwinds through efficiency measures. For US investors, the stock provides exposure to a specialized medtech niche with significant operations in the United States and other developed markets, but it also involves sensitivities to reimbursement decisions, competitive dynamics and exchange-rate movements. How effectively Sonova executes on innovation, integration of acquisitions and geographic expansion will likely remain central topics for market participants following the shares over the coming quarters.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.